AI outperforms traditional tests for fatty liver diagnosis?

NCT ID NCT07305636

Completed Diagnosis Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether artificial intelligence (AI) could more accurately predict liver scarring (fibrosis) in people with metabolic-associated fatty liver disease (MAFLD). Researchers compared AI models using FibroScan and clinical data against standard noninvasive scores like FIB-4 and APRI in 522 Egyptian adults. The goal is to find a better, needle-free way to diagnose fibrosis and reduce the need for liver biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, AI could provide a more accurate, noninvasive way to diagnose liver fibrosis in MAFLD patients, potentially reducing the need for liver biopsies.
What could go wrong: This is a completed study with 522 participants, but AI models may not generalize to other populations or settings. The results need validation before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AI (ARTIFICIAL INTELLIGENCE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AI (ARTIFICIAL INTELLIGENCE) MAFLD

Contacts and locations

Locations

Faculty of Medicine

Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.